Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population

International Journal of Cancer

Volumn 92, Issue 5, 2001, Pages 683-686

  Yamada, Yasushi ^a   Watanabe, Masatoshi ^a   Murata, Mariko ^b   Yamanaka, Mikio ^c   Kubota, Yoshinobu ^d   Ito, Haruo ^c   Katoh, Takahiko ^b   Kawamura, Juichi ^c   Yatani, Ryuichi ^a   Shiraishi, Taizo ^a  

^a MIE UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

CYP17; Hormone related gene; Polymorphism; Prostate cancer; SRD5A2

Indexed keywords

ALANINE; ANDROSTANOLONE; CYTOCHROME P450; CYTOCHROME P450 17; LEUCINE; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE INHIBITOR; STEROID HORMONE; TESTOSTERONE; THREONINE; UNCLASSIFIED DRUG; VALINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CARCINOGENESIS; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; RISK FACTOR; RNA TRANSLATION; STEROID METABOLISM;

ADULT; AGE FACTORS; AGED; ALLELES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0035371666     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010601)92:5<683::AID-IJC1255>3.0.CO;2-4     Document Type: Article

References (17)

1. Possible underestimation of the incidence rate of prostate cancer in Japan
2. Serum testosterone levels in healthy young black and white men
3. Prospective study of sex hormone levels and risk of prostate cancer
4. Genes involved in androgen biosynthesis and the male phenotype
5. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP 17
6. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
7. A polymorphism in the CYP17 gene is associated with prostate cancer risk
8. Prostate cancer associated with CYP17 genotype
9. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect
10. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males
11. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase
12. The A49T mutation in the SRD5A2 gene increases risk for aggressive prostate cancer and prostatic steroid 5α-reductase activity
13. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA
14. Codon 89 polymorphism of the human 5α-steroid reductase type 2 gene
15. Epidemiology and natural history of benign prostatic hyperplasia
16. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer